Tarsus Pharmaceuticals, Inc. (TARS) stock
TARSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 11/303% below fair value
$73.01−4.66 (-6.00%)
Close on Nov 20, 2026Market cap $3.20BP/E –Yield 0.00%
Tarsus Pharmaceuticals free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Tarsus Pharmaceuticals's free cash flow for the twelve months ending Jun 30, 2026 was $56.00M. For fiscal 2025 it was -$22.31M. The highest annual figure on record is $3.16M in fiscal 2021.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$22.31M | – |
| FY2024 | Dec 31, 2024 | -$84.59M | – |
| FY2023 | Dec 31, 2023 | -$119.00M | – |
| FY2022 | Dec 31, 2022 | -$49.54M | -1666.6% |
| FY2021 | Dec 31, 2021 | $3.16M | – |
| FY2020 | Dec 31, 2020 | -$21.59M | – |
| FY2019 | Dec 31, 2019 | -$3.85M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $57.15M | – |
| Q1 FY2026 | Mar 31, 2026 | -$30.47M | – |
| Q4 FY2025 | Dec 31, 2025 | $12.97M | – |
| Q3 FY2025 | Sep 30, 2025 | $16.35M | – |
| Q2 FY2025 | Jun 30, 2025 | -$30.39M | – |
| Q1 FY2025 | Mar 31, 2025 | -$21.24M | – |
| Q4 FY2024 | Dec 31, 2024 | -$22.25M | – |
| Q3 FY2024 | Sep 30, 2024 | -$8.93M | – |
| Q2 FY2024 | Jun 30, 2024 | -$15.44M | – |
| Q1 FY2024 | Mar 31, 2024 | -$37.96M | – |
| Q4 FY2023 | Dec 31, 2023 | -$39.34M | – |
| Q3 FY2023 | Sep 30, 2023 | -$32.74M | – |
| Q2 FY2023 | Jun 30, 2023 | -$24.61M | – |
| Q1 FY2023 | Mar 31, 2023 | -$22.31M | – |
| Q4 FY2022 | Dec 31, 2022 | -$11.00M | – |
| Q3 FY2022 | Sep 30, 2022 | -$18.71M | -367.6% |
| Q2 FY2022 | Jun 30, 2022 | -$4.38M | -121.3% |
| Q1 FY2022 | Mar 31, 2022 | -$15.45M | – |
| Q4 FY2021 | Dec 31, 2021 | -$12.40M | – |
| Q3 FY2021 | Sep 30, 2021 | $6.99M | – |
| Q2 FY2021 | Jun 30, 2021 | $20.54M | – |
| Q1 FY2021 | Mar 31, 2021 | -$11.97M | – |
| Q4 FY2020 | Dec 31, 2020 | -$9.96M | – |
| Q3 FY2020 | Sep 30, 2020 | -$6.71M | – |
| Q2 FY2020 | Jun 30, 2020 | -$2.89M | – |
| Q1 FY2020 | Mar 31, 2020 | -$2.03M | – |
| Q4 FY2019 | Dec 31, 2019 | -$830.00K | – |
See a number that looks wrong?